Lexeo Therapeutics (LXEO) Return on Capital Employed (2023 - 2026)

Lexeo Therapeutics has disclosed Return on Capital Employed across 4 years of filings, most recently posting 39.86% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 39.86%, down 1030.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 39.86% (down 1030.0% YoY), and the FY2025 annual result was 57.2%, down 4005.0% from the prior year.
• Return on Capital Employed came in at 39.86% for Q1 2026 at Lexeo Therapeutics, up from 57.67% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 15.03% in Q4 2024 to a low of 85.61% in Q4 2023.
• The 4-year median for Return on Capital Employed is 42.27% (2024), against an average of 43.11%.
• Across the five-year window, Return on Capital Employed surged 7058 bps in 2024 and slumped 4264 bps in 2025, its largest moves.
• Lexeo Therapeutics' Return on Capital Employed stood at 85.61% in 2023, then soared by 82 bps to 15.03% in 2024, then tumbled by 284 bps to 57.67% in 2025, then jumped by 31 bps to 39.86% in 2026.
• The last three Return on Capital Employed figures came in at 39.86% (Q1 2026), 57.67% (Q4 2025), and 19.92% (Q3 2025), per Business Quant data.